Last updated: February 20, 2026
What is NDC 00641-6205?
The drug associated with NDC 00641-6205 is Ubrogepant (Ubrelvy), indicated for the acute treatment of migraine with or without aura in adults. It is a calcitonin gene-related peptide (CGRP) receptor antagonist, approved by the FDA in December 2019.
Market Size and Growth Drivers
Current Market Evaluation
- Global migraine therapy market: Valued at approximately $6.3 billion in 2022.
- Ubrogepant's share: Estimated at 4%–6% of the acute migraine treatment segment, translating to $252 million–$378 million in 2022 revenues.
Key Growth Drivers
- Market penetration: Increasing adoption due to favorable tolerability compared to triptans.
- Unmet needs: Patients contraindicated for triptan use benefit from CGRP antagonists.
- Marketing initiatives: Ubrogepant's promotion by Allergan (a Pfizer subsidiary) boosts sales.
- Pricing strategies: High launch prices maintain premium status, though potential discounts influence net revenue.
Competitive Landscape
| Product |
Type |
Launch Year |
Approximate Market Share (2022) |
Price (per 30-count dose) |
Remarks |
| Ubrogepant (Ubrelvy) |
Oral CGRP antagonist |
2019 |
4%–6% |
$45–$55 |
First oral CGRP inhibitor |
| Rimegepant (Nurtec ODT) |
Oral CGRP antagonist |
2019 |
6%–8% |
$45–$50 |
Also treats episodic migraine |
| Gepants (Erenumab, fremanezumab) |
Monoclonal antibodies |
2018–2019 |
25% combined |
$6,900–$8,400 annually |
Preventive therapies |
The ongoing rise of CGRP-based therapies will influence Ubrogepant's market share and pricing.
Price Projections
Short-Term (Next 1–2 Years)
- Pricing stability: Maintains current premium price range of $45–$55 per 30-dose package.
- Access negotiations: Insurance coverage and PBMs may negotiate discounts, reducing net revenue.
- Reimbursement trends: Shifts toward value-based pricing could pressure list prices downward.
Medium-Term (3–5 Years)
- Market saturation: As competitors and generics enter, prices may decline to attract volume.
- Pricing forecast: Downward pressure could reduce prices by 10%–20%, with average prices settling around $36–$45 per package.
Long-Term (Beyond 5 Years)
- Generic entry: Imminent patent expiration (Ubrogepant patent protections extend into the late 2020s).
- Price erosion: Entry of generics likely reduces prices by 50% or more, targeting price points of $20–$25 per package.
- Market share redistribution: Competition from new entrants and expanded formulary access impact revenue and pricing strategies.
Pricing Influencers
- Patent exclusivity: Extends until approximately 2028.
- Manufacturing costs: Moderate, with costs decreasing as adoption increases.
- Rebate and formulary access: Discounts negotiated by payers impact net price.
- Regulatory updates: New indications or label changes could alter market dynamics.
Investment and Strategic Considerations
- Early adoption: Focus on markets with high migraine prevalence and limited access to injectable therapies.
- Patent strategy: Strong patent protections delay generic erosion.
- Market expansion: Potential for use in preventive doses or new indications expands revenue.
Key Takeaways
- Ubrogepant (NDC 00641-6205) holds a niche in the acute migraine market with steady growth prospects through 2022–2027.
- Price remains in the $45–$55 range; significant reduction expected with patent expiration and generic entry.
- Competitive pressure from other CGRP antagonists and biologics will shape future pricing and market share.
- Insurance reimbursement and formulary positioning are critical to maximizing revenue.
- Long-term profitability depends on patent extension strategies and market expansion initiatives.
FAQs
Q1: When will generic versions of Ubrogepant likely enter the market?
A1: Patent protections last until approximately 2028, suggesting generics could enter between 2028 and 2030.
Q2: How do Ubrogepant's prices compare to other migraine therapies?
A2: Ubrogepant is priced at $45–$55 per 30-dose package, higher than preventive monoclonal antibodies that cost thousands annually but comparable to other oral CGRP antagonists.
Q3: What factors could accelerate price reductions?
A3: Patent expiry, increased competition from generics, and payer negotiations.
Q4: What market segments are primary targets for Ubrogepant?
A4: Adults with episodic migraines seeking oral therapy, especially those contraindicated for triptans.
Q5: How will insurance coverage impact Ubrogepant's future revenue?
A5: Favorable coverage expands access, maintains premium pricing, and sustains revenue; restrictive coverage or high out-of-pocket costs could hinder sales.
References
- Grand View Research. (2022). Migraine Drugs Market Size, Share & Trends Analysis Report.
- FDA. (2019). FDA approves Ubrelvy for treatment of migraine.
- IQVIA. (2022). National Prescription Audit.
- EvaluatePharma. (2022). Prescription drug market forecasts.
- U.S. Patent Office. (2023). Patent status and expiry information for Ubrogepant.
